Curis to Present at Upcoming Investor Conferences
Curis, Inc. (NASDAQ: CRIS) announced that CEO James Dentzer will present at two investor conferences on September 15, 2020. The first event is the Cantor Fitzgerald Virtual Global Healthcare Conference at 9:20 am ET, followed by the H.C. Wainwright & Co. 22nd Annual Global Investment Conference at 4:30 pm ET. Both presentations will be available via live webcast on the company's website, with replays accessible for 90 days post-event. Curis specializes in cancer therapeutics, with ongoing trials for several innovative drugs.
- None.
- None.
LEXINGTON, Mass., Sept. 10, 2020 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer, President and Chief Executive Officer of Curis, will provide a company overview at two upcoming investor conferences:
- Cantor Fitzgerald Virtual Global Healthcare Conference: Fireside Chat – Tuesday, September 15, 2020 at 9:20 am ET.
- H.C. Wainwright & Co. 22nd Annual Global Investment Conference: Tuesday, September 15, 2020 at 4:30 pm ET.
A live webcast of each presentation will be available under "Events & Presentations" in the Investors section of the Company's website at www.curis.com. A replay of the webcast will be available on the Curis website for 90 days following the event.
About Curis, Inc.
Curis is a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer. In 2015, Curis entered into a collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of immune checkpoints including, the VISTA/PDL1 antagonist CA-170, and the TIM3/PDL1 antagonist CA-327, as well as the IRAK4 kinase inhibitor, CA-4948. CA-4948 is currently undergoing testing in a Phase 1 trial in patients with non-Hodgkin lymphoma and in a Phase 1 trial in patients with acute myeloid leukemia and myelodysplastic syndromes. In addition, Curis is engaged in a collaboration with ImmuNext for development of CI-8993, a monoclonal anti-VISTA antibody, which is planned to be tested in a Phase 1a/1b trial in patients with solid tumors. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge® for the treatment of advanced basal cell carcinoma. For more information, visit Curis' website at www.curis.com.
View original content to download multimedia:http://www.prnewswire.com/news-releases/curis-to-present-at-upcoming-investor-conferences-301127921.html
SOURCE Curis, Inc.
FAQ
What presentations will Curis, Inc. CEO James Dentzer give on September 15, 2020?
Where can I watch the live webcasts of Curis, Inc.'s presentations?
What is the focus of Curis, Inc. as a biotechnology company?
What are some of the drugs Curis, Inc. is currently testing?
How long will the webcasts of the conferences be available for replay?
